Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 1.29
- Piotroski Score 3.00
- Grade Buy
- Symbol (IMCR)
- Company Immunocore Holdings plc
- Price $32.84
- Changes Percentage (2.24%)
- Change $0.72
- Day Low $32.13
- Day High $33.20
- Year High $76.98
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/26/2025
- Fiscal Year End N/A
- Average Stock Price Target $70.00
- High Stock Price Target $100.00
- Low Stock Price Target $24.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.56
- Trailing P/E Ratio -26.72
- Forward P/E Ratio -26.72
- P/E Growth -26.72
- Net Income $-55,287,000
Income Statement
Quarterly
Annual
Latest News of IMCR
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Is Immunocore Holdings plc (IMCR) the Best Immunotherapy Stock to Buy Now?
Discover the top immunotherapy stocks to invest in now. The global immunotherapy market is booming, set to grow exponentially due to the rise in chronic diseases like cancer. Immunotherapy is proving ...
By Yahoo! Finance | 4 days ago -
Immunocore Holdings plc (IMCR): Worst 52-Week Low Stock to Buy Now
The recent interest rate cut by the U.S. Federal Reserve has boosted stock market sentiments, with the Nasdaq 100 showing significant gains. The rate cut is expected to lower borrowing costs, benefitt...
By Yahoo! Finance | 1 month ago -
Immunocore Holdings plc (NASDAQ:IMCR) Ranks Low On The List Of Worst Falling Stocks To Buy
The article discusses the performance of falling stocks such as Immunocore Holdings plc on the market. It highlights factors influencing stock performance, including fundamentals and market sentiment....
By Yahoo! Finance | 1 month ago
